Philipp Staber

23PUBLICATIONS
155CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersMedical infection agents (incl. prions)Medical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Mar 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht

|Feb 24, 2026
Impact of Perforin 1 A91V germ line background in patients with aggressive B-NHL treated with R-CHOP.

Onur Cetin, Igor Kos, Evi Regitz

|Feb 19, 2026
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.

Daniel Filip, Katerina Litzmanova, Androniki Michaelou

|Dec 08, 2025
Impact of Perforin 1 A91V germ line background in patients with aggressive B-NHL treated with R-CHOP.

Onur Cetin, Igor Kos, Evi Regitz

|Aug 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza

|Dec 16, 2024
Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets.

Alexander S Pichler, Catalina Amador, Ayumi Fujimoto

Pageof 4

Frequent Collaborators

6 joint publications

Michael J Hallek

6 joint publications

Carsten Utoft Niemann

5 joint publications

Arnon P Kater

5 joint publications

Florian Simon